HomeCompareMSBHF vs ABBV

MSBHF vs ABBV: Dividend Comparison 2026

MSBHF yields 2.17% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSBHF wins by $76.68M in total portfolio value· pulled ahead in Year 4
10 years
MSBHF
MSBHF
● Live price
2.17%
Share price
$34.97
Annual div
$0.76
5Y div CAGR
98.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.79M
Annual income
$70,226,249.12
Full MSBHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MSBHF vs ABBV

📍 MSBHF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSBHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSBHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSBHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSBHF
Annual income on $10K today (after 15% tax)
$184.73/yr
After 10yr DRIP, annual income (after tax)
$59,692,311.75/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MSBHF beats the other by $59,671,255.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSBHF + ABBV for your $10,000?

MSBHF: 50%ABBV: 50%
100% ABBV50/50100% MSBHF
Portfolio after 10yr
$38.44M
Annual income
$35,125,510.44/yr
Blended yield
91.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MSBHF
No analyst data
Altman Z
2.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSBHF buys
0
ABBV buys
0
No recent congressional trades found for MSBHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSBHFABBV
Forward yield2.17%3.06%
Annual dividend / share$0.76$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR98.9%40.6%
Portfolio after 10y$76.79M$102.3K
Annual income after 10y$70,226,249.12$24,771.77
Total dividends collected$76.26M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSBHF vs ABBV ($10,000, DRIP)

YearMSBHF PortfolioMSBHF Income/yrABBV PortfolioABBV Income/yrGap
1$11,132$432.27$11,550$430.00$418.00ABBV
2$12,806$894.51$13,472$627.96$666.00ABBV
3$15,615$1,912.80$15,906$926.08$291.00ABBV
4← crossover$21,044$4,335.66$19,071$1,382.55+$2.0KMSBHF
5$33,378$10,861.38$23,302$2,095.81+$10.1KMSBHF
6$67,739$32,023.88$29,150$3,237.93+$38.6KMSBHF
7$193,289$120,808.19$37,536$5,121.41+$155.8KMSBHF
8$847,610$640,790.84$50,079$8,338.38+$797.5KMSBHF
9$6,130,384$5,223,441.57$69,753$14,065.80+$6.06MMSBHF
10$76,785,760$70,226,249.12$102,337$24,771.77+$76.68MMSBHF

MSBHF vs ABBV: Complete Analysis 2026

MSBHFStock

Mitsubishi Corporation engages in the natural gas, industrial materials, petroleum and chemicals, mineral resources, industrial infrastructure, automotive and mobility, food and consumer industry, power solution, and urban development businesses worldwide. The company's Natural Gas segment is involved in the natural gas/oil exploration, production, and development, as well as liquified natural gas businesses. Its Industrial Materials segment invests in, develops, and trades in carbon, steel products, and performance materials for the automobile and mobility, construction, and infrastructure industries. The company's Petroleum & Chemicals segment invests in, develops, and trades in crude oil and oil products, LPG, ethylene, methanol, salt, ammonia, plastics, and fertilizers. Its Mineral Resources segment invests in and develops metallurgical coal, copper, iron ore, and aluminum resources. The company's Industrial Infrastructure segment trades in energy infrastructure, industrial plants, machinery tools, agricultural machinery, mining machinery, elevators, escalators, ships, and aerospace related equipment. Its Automotive & Mobility segment produces, finances, and sells passenger and commercial cars; and mobility services. The company's Food Industry segment develops and sells food resources, fresh foods, consumer goods, and food ingredients. Its Consumer Industry segment engages in supplying products and services a range of fields, including retail & distribution, logistics, healthcare, apparel, and tire, etc. The company's Power Solution segment generates, transmits, and retails power; supplies power generating and transmitting products and equipment; develops and sells lithium-ion battery; develops hydrogen; and offers battery services. Its Urban Development segment engages in the leasing; and urban infrastructure and real estate development, operation, and management businesses. The company was incorporated in 1950 and is headquartered in Tokyo, Japan.

Full MSBHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MSBHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSBHF vs SCHDMSBHF vs JEPIMSBHF vs OMSBHF vs KOMSBHF vs MAINMSBHF vs JNJMSBHF vs MRKMSBHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.